Loading...
XLONFDBK
Market cap9mUSD
Dec 23, Last price  
16.75GBP
1D
0.00%
1Q
-61.93%
Jan 2017
-96.03%
Name

Feedback PLC

Chart & Performance

D1W1MN
XLON:FDBK chart
P/E
—
P/S
621.13
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
51.05%
Rev. gr., 5y
15.98%
Revenues
1m
+15.27%
9,179,0007,639,0009,639,0009,607,0008,163,0007,443,0006,308,0002,111,00007,250381,970431,454465,885458,389563,092449,983287,415588,5761,024,9961,181,544
Net income
-3m
L+13.03%
56,000-295,000-646,0007,182,000647,000-441,000-862,000-1,819,000-348,000-470,654-1,111,433-183,156-266,003-630,787-973,109-1,087,457-1,619,513-2,118,591-2,918,177-3,298,367
CFO
-2m
L+22.08%
976,70015,000-74,000738,000230,000359,000452,000-117,000133,000-481,705-641,738-205,105-90,605-357,585-983,191-786,041-2,032,484-1,251,580-1,742,511-2,127,208
Dividend
Jul 10, 19950.4959 GBP/sh
Earnings
Feb 19, 2025

Profile

Feedback plc, a medical imaging technology company, provides software and systems to those working in the field of medical imaging. Its products include TexRAD, a patent-protected software tool, which extracts and quantifies texture features in radiological images, assists research into all tumour types, and uncovers biomarkers in medical images; and TexRAD Lung, a software tool for the analysis of lung cancer for clinical use in the European Union. The company also offers Cadran image platform that provides hospitals and research institutes with a comprehensive picture archiving communication system for medical images, as well as equips users with a platform for image handling from all imaging modalities, such as CT and PET scanners; and Bleepa, a secure clinical communications platform that facilitates the sharing of clinical-grade medical images. Feedback plc was incorporated in 1958 and is headquartered in London, the United Kingdom.
URL
https://fbkmed.com/feedback-plc/
IPO date
Jan 08, 1986
Employees
19
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑052016‑052015‑05
Income
Revenues
1,182
15.27%
1,025
74.15%
589
104.78%
Cost of revenue
1,037
1,675
1,177
Unusual Expense (Income)
NOPBT
145
(650)
(589)
NOPBT Margin
12.26%
Operating Taxes
(299)
(456)
(393)
Tax Rate
NOPAT
443
(194)
(196)
Net income
(3,298)
13.03%
(2,918)
37.74%
(2,119)
30.82%
Dividends
Dividend yield
Proceeds from repurchase of equity
10,490
10,491
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
4
Other long-term liabilities
Net debt
(3,878)
(7,318)
(10,306)
Cash flow
Cash from operating activities
(2,127)
(1,743)
(1,252)
CAPEX
(1,313)
(1,245)
(1,155)
Cash from investing activities
(1,313)
(1,245)
(1,155)
Cash from financing activities
(830)
10,491
FCF
445
(94)
59
Balance
Cash
3,878
7,318
10,306
Long term investments
Excess cash
3,818
7,266
10,276
Stockholders' equity
(8,398)
(4,481)
(1,642)
Invested Capital
16,043
15,203
15,285
ROIC
2.84%
ROCE
1.89%
EV
Common stock shares outstanding
13,335
13,335
9,346
Price
Market cap
EV
EBITDA
1,102
159
(36)
EV/EBITDA
Interest
Interest/NOPBT